Physician profile
William D Adams
NPI 1467403733
$3,782.50
in general payments reported to CMS, 2019-2025
37 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $474 · 2021: $711 · 2022: $525 · 2023: $362 · 2024: $597 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,461.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $864.67 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $317.71 | 2019-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $310.42 | 2019-2025 | Veozah |
| Amgen INC. | $264.23 | 2019-2023 | Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $218.36 | 2019-2021 | |
| Lilly USA, LLC | $207.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $200.99 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.30 | 2020-2024 | Xifaxan, Trulance |
| Pfizer INC. | $146.36 | 2019-2025 | |
| Novo Nordisk INC | $121.43 | 2019-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.09 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $89.01 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $78.91 | 2021-2022 | |
| Boston Scientific Corporation | $70.62 | 2021-2025 | General - Pain Management |
| Axsome Therapeutics, INC. | $63.79 | 2023-2025 | Auvelity |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.